Understanding drug resistance in HIV treatments across different virus types
Drug Resistance Genotypic and Phenotypic Correlates of Efavirenz and Dolutegravir based Treatment Outcomes across Non-B HIV-1 subtypes
This study is looking at how different types of HIV, especially those that aren't the common B type, react to certain medications, and it's aimed at helping people living with HIV by finding out why some strains resist treatment, especially in places where resources are limited.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Seattle Children's Hospital NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project ID | NIH-10662274 on NIH RePORTER |
What this research studies
This research investigates how different strains of HIV, particularly non-B subtypes, respond to antiretroviral therapies like Efavirenz and Dolutegravir. It aims to identify the genetic and phenotypic factors that contribute to drug resistance in these strains, which is crucial for improving treatment outcomes. By analyzing data from patients in resource-limited settings, the study seeks to enhance our understanding of how drug resistance affects viral suppression and overall health in people living with HIV. The findings could inform better treatment strategies tailored to diverse populations.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults living with HIV, particularly those infected with non-B subtypes of the virus.
Not a fit: Patients who are not infected with HIV or those with only subtype B infections may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective HIV treatment options for patients infected with non-B subtypes of the virus.
How similar studies have performed: While there has been significant research on drug resistance in HIV, this study focuses specifically on non-B subtypes, which has been less explored, making it a novel approach.
Where this research is happening
Seattle, United States
- Seattle Children's Hospital — Seattle, United States (Active)
Researchers
- Principal investigator: Frenkel, Lisa M — Seattle Children's Hospital
- Study coordinator: Frenkel, Lisa M
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.